Abstract
B7-H4 (VTCN1, B7x, B7s) is an inhibitory modulator of T-cell response implicated in antigen tolerization. As such, B7-H4 is an immune checkpoint of potential therapeutic interest. To generate anti-B7-H4 targeting reagents, we isolated antibodies by differential cell screening of a yeast-display library of recombinant antibodies (scFvs) derived from ovarian cancer patients and we screened for functional scFvs capable to interfere with B7-H4-mediated inhibition of antitumor responses. We found one antibody binding to B7-H4 that could restore antitumor T cell responses. This chapter gives an overview of the methods we developed to isolate a functional anti-B7-H4 antibody fragment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sica GL, Choi IH, Zhu G et al (2003) B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18:849–861, doi:S1074761303001523 [pii]
Prasad DV, Richards S, Mai XM et al (2003) B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 18:863–873, doi:S107476130300147X [pii]
Zang X, Loke P, Kim J et al (2003) B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A 100:10388–10392. doi:10.1073/pnas.1434299100, 1434299100 [pii]
Kryczek I, Wei S, Zou L et al (2006) Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol 177:40–44, doi:177/1/40 [pii]
Tringler B, Zhuo S, Pilkington G et al (2005) B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res 11:1842–1848. doi:10.1158/1078-0432.CCR-04-1658, 11/5/1842 [pii]
Kryczek I, Zou L, Rodriguez P et al (2006) B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 203:871–881. doi:10.1084/jem.20050930, jem.20050930 [pii]
Choi IH, Zhu G, Sica GL et al (2003) Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol 171:4650–4654
Sun Y, Wang Y, Zhao J et al (2006) B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 53:143–151. doi:10.1016/j.lungcan.2006.05.012, S0169-5002(06)00231-5 [pii]
Quandt D, Fiedler E, Boettcher D et al (2011) B7-h4 expression in human melanoma: its association with patients’ survival and antitumor immune response. Clin Cancer Res 17:3100–3111. doi:10.1158/1078-0432.CCR-10-2268, 1078-0432.CCR-10-2268 [pii]
Krambeck AE, Thompson RH, Dong H et al (2006) B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A 103:10391–10396. doi:10.1073/pnas.0600937103, 0600937103 [pii]
Jiang J, Zhu Y, Wu C et al (2010) Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother 59:1707–1714. doi:10.1007/s00262-010-0900-7
Miyatake T, Tringler B, Liu W et al (2007) B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol Oncol 106:119–127. doi:10.1016/j.ygyno.2007.03.039, S0090-8258(07)00198-9 [pii]
Zang X, Thompson RH, Al-Ahmadie HA et al (2007) B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A 104:19458–19463. doi:10.1073/pnas.0709802104, 0709802104 [pii]
van der Meel R, Gallagher WM, Oliveira S et al (2010) Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies. Drug Discov Today 15:102–114. doi:10.1016/j.drudis.2009.12.003, S1359-6446(09)00405-X [pii]
Porter DL, Kalos M, Zheng Z et al (2011) Chimeric antigen receptor therapy for B-cell malignancies. J Cancer 2:331–332
Dangaj D, Lanitis E, Zhao A et al (2013) Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses. Cancer Res 73:4820–4829. doi:10.1158/0008-5472.CAN-12-3457
Zhao A, Nunez-Cruz S, Li C et al (2011) Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform. J Immunol Methods 363:221–232. doi:10.1016/j.jim.2010.09.001, S0022-1759(10)00239-5 [pii]
Scholler N (2012) Selection of antibody fragments by yeast display. Methods Mol Biol 907:259–280. doi:10.1007/978-1-61779-974-7_15
Durocher Y, Perret S, Kamen A (2002) High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 30:E9
Lanitis E, Poussin M, Hagemann IS et al (2012) Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol Ther 20:633–643. doi:10.1038/mt.2011.256, mt2011256 [pii]
Dangaj D, Abbott KL, Mookerjee A et al (2011) Mannose receptor (MR) engagement by mesothelin GPI anchor polarizes tumor-associated macrophages and is blocked by anti-MR human recombinant antibody. PLoS One 6:e28386. doi:10.1371/journal.pone.0028386, PONE-D-11-09405 [pii]
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Dangaj, D., Scholler, N. (2015). Isolation and Validation of Anti-B7-H4 scFvs from an Ovarian Cancer scFv Yeast-Display Library. In: Liu, B. (eds) Yeast Surface Display. Methods in Molecular Biology, vol 1319. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2748-7_2
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2748-7_2
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2747-0
Online ISBN: 978-1-4939-2748-7
eBook Packages: Springer Protocols